DFDA

High-dose Moxifloxacin-based Regimen

Treatment for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance

Typical Dosage: Moxifloxacin 400-800mg daily, combined with other second-line drugs

Effectiveness
72%
Safety Score
62%
Clinical Trials
40
Participants
6K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
62
DangerousModerateSafe
Treatment Details
Dosage Range
Moxifloxacin 400-800mg daily, combined with other second-line drugs
Time to Effect
2-3 months for culture conversion
Treatment Duration
18-24 months
Evidence Quality
MODERATE
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$4,000
Side Effect Mgmt:$2,500
Total Annual:$11,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$50,000/QALY
QALYs Gained
0.45
Outcome-Based Costs
Cost per Responder
$15,753
Cost per Remission
$16,912
Comparison vs Injectable-containing MDR-TB regimen
Cost Difference
$-4,000/year
Less expensive
QALY Difference
+0.08 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
High-dose Moxifloxacin-based Regimen Outcomes

for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance

Efficacy Outcomes
Overall Effectiveness
+72%
Response Rate
+73%
Remission Rate
+68%
Common Side Effects
QT prolongation
+15%
Gastrointestinal upset
+15%
Tendonitis/rupture
+3%
CNS effects (dizziness, insomnia)
+7%

Sources:

asm.org
nih.gov
oup.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov